BioCardia Inc (BCDA)
2.40
+0.01
(+0.42%)
USD |
NASDAQ |
Nov 04, 13:04
BioCardia Revenue (Quarterly): 0.003M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.003M |
| March 31, 2024 | 0.055M |
| December 31, 2023 | 0.013M |
| September 30, 2023 | 0.357M |
| June 30, 2023 | 0.043M |
| March 31, 2023 | 0.064M |
| December 31, 2022 | 0.106M |
| September 30, 2022 | 0.212M |
| June 30, 2022 | 0.974M |
| March 31, 2022 | 0.06M |
| December 31, 2021 | 0.079M |
| September 30, 2021 | 0.821M |
| June 30, 2021 | 0.069M |
| March 31, 2021 | 0.046M |
| December 31, 2020 | 0.046M |
| September 30, 2020 | 0.034M |
| June 30, 2020 | 0.027M |
| March 31, 2020 | 0.038M |
| December 31, 2019 | 0.215M |
| September 30, 2019 | 0.194M |
| June 30, 2019 | 0.086M |
| March 31, 2019 | 0.216M |
| December 31, 2018 | 0.103M |
| September 30, 2018 | 0.084M |
| June 30, 2018 | 0.239M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.199M |
| December 31, 2017 | 0.10M |
| September 30, 2017 | 0.13M |
| June 30, 2017 | 0.112M |
| March 31, 2017 | 0.137M |
| December 31, 2016 | -5.215M |
| September 30, 2016 | 5.50M |
| June 30, 2016 | 0.142M |
| March 31, 2016 | 0.149M |
| December 31, 2015 | 0.135M |
| September 30, 2015 | 0.121M |
| June 30, 2015 | 0.125M |
| March 31, 2015 | 0.136M |
| December 31, 2014 | 0.128M |
| September 30, 2014 | 0.096M |
| June 30, 2014 | 0.105M |
| March 31, 2014 | 0.098M |
| December 31, 2013 | 0.09M |
| September 30, 2013 | 0.071M |
| June 30, 2013 | 0.069M |
| March 31, 2013 | 0.038M |
| December 31, 2012 | 0.015M |
| September 30, 2012 | 0.019M |
| June 30, 2012 | 0.017M |
| March 31, 2012 | 0.011M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.003M
Minimum
Jun 2024
0.974M
Maximum
Jun 2022
0.1717M
Average
0.06M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 500.92M |
| Theriva Biologics Inc | -- |
| Zevra Therapeutics Inc | 4.449M |
| PetIQ Inc | 328.94M |
| Instil Bio Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.646M |
| Total Expenses (Quarterly) | 1.652M |
| EPS Diluted (Quarterly) | -0.88 |
| Enterprise Value | 3.655M |
| Profit Margin (Quarterly) | -54.87K% |
| Earnings Yield | -224.2% |
| Normalized Earnings Yield | -224.17 |